Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography–tandem mass spectrometry
- 1 July 2005
- journal article
- Published by Elsevier BV in Journal of Chromatography A
- Vol. 1082 (1), 2-5
- https://doi.org/10.1016/j.chroma.2005.04.043
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometryJournal of Chromatography A, 2003
- A sensitive assay for ZD1839 (Iressa) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trialsJournal of Pharmaceutical and Biomedical Analysis, 2002
- Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy VolunteersClinical Pharmacokinetics, 2001
- Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancerCancer Gene Therapy, 1999
- Antisense oligonucleotides to the epidermal growth factor receptorBreast Cancer Research and Treatment, 1999
- American Association for Cancer Research 1997: progress and new hope in the fight against cancerExpert Opinion on Investigational Drugs, 1997
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996